Long-term follow-up more than 10 years after HSCT: a monocentric experience.

about

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

Item

http://www.wikidata.org/entity/Q47261875

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

@en

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

@nl

type

Item

label

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

@en

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

@nl

prefLabel

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

@en

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

@nl

P1476

Long-term follow-up more than 10 years after HSCT: a monocentric experience.

@en

P2093

Adriana Vacca

http://www.w3.org/2001/XMLSchema#string

Elena Mamusa

http://www.w3.org/2001/XMLSchema#string

Giancarlo Coghe

http://www.w3.org/2001/XMLSchema#string

Giorgio La Nasa

http://www.w3.org/2001/XMLSchema#string

Giuseppe Fenu

http://www.w3.org/2001/XMLSchema#string

Jessica Frau

http://www.w3.org/2001/XMLSchema#string

Lorena Lorefice

http://www.w3.org/2001/XMLSchema#string

Margherita Carai

http://www.w3.org/2001/XMLSchema#string

Maria Giovanna Marrosu

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

Classifying PML risk with disease modifying therapies.

Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience.

New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review.

New management algorithms in multiple sclerosis.

P2888

s00415-017-8718-2

P304

410-416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-017-8718-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

265

http://www.w3.org/2001/XMLSchema#string

P50

Eleonora Cocco

P577

2017-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29270686

http://www.w3.org/2001/XMLSchema#string